Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. REGENXBIO Inc.
  6. News
  7. Summary
    RGNX   US75901B1070

REGENXBIO INC.

(RGNX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

REGENXBIO INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)

10/12/2021 | 06:10am EST

Item 7.01. Regulation FD Disclosure.

On October 9, 2021, Dennis Marcus, M.D., F.A.S.R.S., President, Southeast Retina Center, and a principal investigator for REGENXBIO Inc.'s (the "Company") Phase II ALTITUDE clinical trial utilizing in-office suprachoroidal delivery of RGX-314 for the treatment of diabetic retinopathy, presented an interim analysis of data from the ALTITUDE trial at the American Society of Retina Specialists Annual Meeting. A copy of Dr. Marcus' presentation materials is available on the "Presentations and Publications" section of the Company's website at www.regenxbio.com.

The information in Item 7.01 of this Current Report on Form 8-K and the presentation materials on the Company's website shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.



Item 8.01. Other Events.


On October 9, 2021, the Company issued a press release announcing an interim analysis of data from the ALTITUDE trial. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.


(d)  Exhibits



Exhibit No.       Description

99.1                Press release dated October 9, 2021.

104               The cover page from this Current Report on Form 8-K, formatted in
                  Inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about REGENXBIO INC.
11/22Regenxbio Gets FDA Orphan Drug Designation for Muscular Dystrophy Gene Therapy Candidat..
MT
11/22REGENXBIO Inc. Announces Orphan Drug Designation Granted to RGX-202, A Novel Gene Thera..
CI
11/15REGENXBIO INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
11/12REGENXBIO : Presents Additional Positive Interim Data from Trials of RGX-314 in Wet AMD an..
PU
11/12REGENXBIO INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits..
AQ
11/12REGENXBIO Inc. Presents Additional Positive Interim Data from Trials of RGX-314 in Wet ..
CI
11/09REGENXBIO Announces Closing of Eye Care Collaboration Agreement with AbbVie - Form 8-K
PU
11/09REGENXBIO INC. : Other Events, Regulation FD Disclosure, Financial Statements and Exhibits..
AQ
11/09REGENXBIO Inc. Announces Closing of Eye Care Collaboration Agreement with AbbVie
CI
11/08REGENXBIO to Participate in Upcoming Investor Conferences
PR
More news
Analyst Recommendations on REGENXBIO INC.
More recommendations